President's Symposium

The challenges in pursuit of identifying effective treatments for the highly complex and fatal idiopathic pulmonary fibrosis (IPF) will be the focus of the Sunday, May 20, President’s Symposium, “Drugs, Regulatory Agencies and Guidelines: The Challenge of Idiopathic Pulmonary Fibrosis.”

Speakers will emphasize the importance of clinically meaningful outcomes for afflicted patient to be used for primary endpoints in phase III IPF clinical trials. The benefits and the pitfalls of evidence-based versus consensus of expert opinion-based guidelines will be discussed. The audience will get better insight to the challenges of phase III IPF clinical trials and the approval process of drugs indicated for the treatment of IPF by regulatory agencies in the United States and Europe.